Q1 FY27 Results: Revenue up 30% YoY, PAT more than doubles

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterResults View source PDF

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.3%1-day move

₹1682.20

prior close

₹1621.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+7.5+9.7+9.7+9.7+0.3-1.9-2.1-6.5——————

Up moveDown movePending

AI summary

Venus Remedies Q1FY27 standalone revenue grew 30% YoY to Rs 178.80 Cr from Rs 137.13 Cr. Net profit more than doubled to Rs 25.53 Cr from Rs 11.70 Cr. EBITDA rose to Rs 39.11 Cr from Rs 20.66 Cr. Consolidated PAT reached Rs 22.97 Cr vs Rs 9.60 Cr. Auditor flagged emphasis of matter on Rs 28.60 Cr pending share application money in German subsidiary Venus Pharma GmbH facing financial challenges. Board also approved MOA revisions to align with Companies Act 2013, expanding scope to include biotech, digital and telehealth businesses, pending shareholder approval.

Likely market impact

Strong Q1 with over 30% revenue growth and more than doubled profit. Watch German subsidiary exposure needing ongoing support.